Clinical Trial Update: Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rituximab for treatment-refractory hypersensitivity pneumonitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypersensitivity Pneumonitis
• Interstitial Lung Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Shereen Medhat Mohammed Elsayed Nassar | Conditions: Hypersenstivity Pneumonitis, ILD | Phase 2 | Status: COMPLETED